Mast cell

Lore & Background

They develop from circulating mast cell progenitors (MCps) that, once recruited to connective or mucosal tissue, specialize and become resident mast cells. Mature MCs exhibit context-specific effector properties related to tissue types and diseases, and are highly varied. Mast cells in different tissues, such as gut and skin, exhibit different physical, behavioral, and biochemical characteristics and functions. The earliest source of mast cells in vertebrates is the extraembryonic yolk sac, where blood and immune cells first develop. During embryonic development, mast cell progenitors form in a series of developmentally discrete waves, with the first wave derived from erythro-myeloid progenitors in the yolk sac before hematopoietic stem cells emerge.

Reader's Guide

Mast cells are highly versatile immune cells that first appear during fetal development. They are present in most tissues and characteristically surround blood vessels, nerves and lymphatic vessels, especially near boundaries between the outside world and the internal milieu, such as the skin, mucosa of the lungs, and digestive tract. Mature resident mast cells are categorized based on tissue location, granule protease content, and functional characteristics. In rodents, the two major categories are connective tissue-resident mast cells (CTMCs) and mucosal mast cells (MMCs). In humans, three main categories have been identified: MCT (expresses tryptase, resides in mucosa of lung and small intestine), MCTC (expresses tryptase, chymase, and carboxypeptidase, resides in skin, lymph nodes, and lung and gut submucosa), and MCC (expresses chymase but not tryptase). Mast cells are still heterogeneous within these main categories. Their significance lies in their ancient evolutionary origin, their sentinel role in immune surveillance, and their involvement in both protective responses and allergic diseases. The debate over whether mast cells originate mostly independent of hematopoietic stem cells or from bone marrow HSCs remains unresolved.

Did You Know?

• In humans, the first yolk sac-derived mast cells originate from mesodermal precursors starting around three weeks into gestation.
• Mast cells are especially prominent near boundaries between the outside world and the internal milieu, such as the skin, mucosa of the lungs, and digestive tract.

A Condition That Touches Nearly Every System

Mast cell activation syndrome occupies a peculiar place in immunology: it is a disorder in which the body's own sentinel cells turn against it. Mast cells, a category of white blood cell normally tasked with defending against pathogens, begin releasing their chemical arsenal—histamine among the most prominent—without adequate provocation. The result is a chronic, multi-system condition whose symptoms can range from mild digestive unease to life-threatening anaphylactic episodes. Because degranulation events can occur in virtually any tissue, patients may simultaneously experience flushing and hives on the skin, lightheadedness and arrhythmia in the cardiovascular system, cramping and reflux in the gut, brain fog and sleep disruption in the nervous system, and wheezing or congestion in the airways. A defining feature is the unpredictable, waxing-and-waning course: severity and duration shift over time, making the condition feel as though it is constantly rearranging itself. Importantly, many of these manifestations overlap with those seen in mastocytosis, since both stem from an excess of mediator release. What distinguishes MCAS as a formal diagnosis, however, is the requirement that symptoms cross into at least two organ systems, confirming a systemic rather than purely local process.

Genetics, Subclasses, and the Cellular Machinery

Researchers have identified a genetic thread running through many MCAS cases, particularly mutations in the KIT gene, whose protein product governs mast cell growth and survival. What sets MCAS apart, however, is that affected individuals often carry a broader scatter of KIT mutations across multiple protein domains, sometimes several simultaneously. This multiplicity may help explain why the syndrome presents with such heterogeneous symptom profiles. The chemical payload released during degranulation includes histamine, leukotrienes, prostaglandins, and tryptase, each contributing to different organ-level effects. Mechanistically, MCAS is further divided into subclasses. In primary MCAS, the threshold for mediator release is abnormally low, and some patients show a measurable overpopulation of mast cells in the bone marrow. Secondary MCAS, the more prevalent form, is triggered by IgE-mediated pathways involving allergens or medications, or by non-IgE pathways such as exercise. Idiopathic MCAS is diagnosed when workups, including bone marrow biopsy, reveal no clonal or allergic cause.

The Diagnostic Maze

Pinpointing MCAS is notoriously difficult. The syndrome's hallmark is its heterogeneity: symptoms are numerous, non-specific, and often lack the dramatic acute presentation that would immediately alert a clinician. A patient might present with intermittent flushing, a bout of diarrhea, and a headache, none of which in isolation points to mast cell pathology. The American Academy of Allergy, Asthma, and Immunology regards a bone marrow biopsy with aspirate as the most precise diagnostic tool, a method borrowed from systemic mastocytosis workups. For clonal MCAS, KIT-D816X mutational analysis and flow cytometry seeking co-expression of CD117 and CD25 are recommended. Notably, the World Health Organization has not yet published its own diagnostic criteria for the condition.

Managing the Storm and Its Companions

Because MCAS symptoms are chronic, fluctuating, and multi-system, management is inherently layered and often requires a combination of pharmacological agents. Mast cell stabilizers sit at the foundation of treatment; cromolyn sodium is the prototypical drug, while natural compounds such as quercetin serve as additional stabilizers to blunt degranulation. H1-antihistamines—cetirizine and fexofenadine among them—counteract the histamine-driven effects that produce flushing, itching, and wheezing. For more severe or IgE-driven cases, anti-IgE therapies can directly dampen the allergic cascade that triggers mast cell activation. Beyond pharmacology, the condition rarely travels alone. Common comorbidities include postural orthostatic tachycardia syndrome, Ehlers-Danlos syndrome, myalgic encephalomyelitis/chronic fatigue syndrome, and Long COVID, each of which can compound the fatigue, pain, and systemic symptoms already present in MCAS. The waxing-and-waning nature of the syndrome means that patients often experience periods of relative calm punctuated by flares that can range from a mild skin reaction to a full anaphylactic episode. This unpredictability, combined with the fact that localized tissue-level activation—such as urticaria or allergic rhinitis—does not meet the threshold for a systemic MCAS diagnosis, adds another layer of complexity to both daily life and clinical management.